Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

The BNT162b2 mRNA COVID-19 vaccine showed high efficacy in clinical trials but observational data from populations not included in trials are needed. We describe immunogenicity 21 days post-dose 1 among 514 Israeli healthcare workers by age, ethnicity, sex and prior COVID-19 infection. Immunogenicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu Jabal, Kamal, Ben-Amram, Hila, Beiruti, Karine, Batheesh, Yunis, Sussan, Christian, Zarka, Salman, Edelstein, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879501/
https://www.ncbi.nlm.nih.gov/pubmed/33573712
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.6.2100096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879501/
https://www.ncbi.nlm.nih.gov/pubmed/33573712
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.6.2100096

Ejemplares similares